NCT05286801 2026-03-18Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsNational Cancer Institute (NCI)Phase 1/2 Active not recruiting86 enrolled
NCT05000294 2026-02-18Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesUniversity of FloridaPhase 1/2 Suspended29 enrolled